Notable Price Action: A Reversal for Edwards Lifesciences Corp Is Not Near. The Stock Rises Again

Notable Price Action: A Reversal for Edwards Lifesciences Corp Is Not Near. The Stock Rises Again

The stock of Edwards Lifesciences Corp (NYSE:EW) is a huge mover today! About 831,338 shares traded hands. Edwards Lifesciences Corp (NYSE:EW) has declined 22.55% since April 26, 2016 and is downtrending. It has underperformed by 27.81% the S&P500.
The move comes after 5 months positive chart setup for the $17.81B company. It was reported on Nov, 29 by We have $88.17 PT which if reached, will make NYSE:EW worth $712.40M more.

Analysts await Edwards Lifesciences Corp (NYSE:EW) to report earnings on February, 7. They expect $0.73 earnings per share, up 15.87% or $0.10 from last year’s $0.63 per share. EW’s profit will be $153.35 million for 29.03 P/E if the $0.73 EPS becomes a reality. After $0.68 actual earnings per share reported by Edwards Lifesciences Corp for the previous quarter, Wall Street now forecasts 7.35% EPS growth.

Edwards Lifesciences Corp (NYSE:EW) Ratings Coverage

Out of 25 analysts covering Edwards Lifesciences Corp (NYSE:EW), 19 rate it a “Buy”, 1 “Sell”, while 5 “Hold”. This means 76% are positive. Edwards Lifesciences Corp has been the topic of 52 analyst reports since July 30, 2015 according to StockzIntelligence Inc. As per Friday, January 8, the company rating was initiated by Suntrust Robinson. The company was maintained on Wednesday, April 27 by Cowen & Co. The firm earned “Outperform” rating on Monday, April 4 by Leerink Swann. The rating was maintained by RBC Capital Markets with “Outperform” on Wednesday, October 26. The firm has “Buy” rating by Jefferies given on Monday, April 4. The rating was maintained by Canaccord Genuity on Wednesday, February 3 with “Buy”. The stock has “Outperform” rating given by Northland Capital on Tuesday, November 8. The firm has “Neutral” rating given on Thursday, June 9 by Guggenheim. The firm earned “Neutral” rating on Monday, March 7 by SunTrust. The firm has “Sell” rating given on Thursday, November 12 by Citigroup.

According to Zacks Investment Research, “Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company’s products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.”

Another recent and important Edwards Lifesciences Corp (NYSE:EW) news was published by which published an article titled: “Edwards Lifesciences to buy Israel’s Valtech for up to $690 million” on November 28, 2016.

EW Company Profile

Edwards Lifesciences Corporation, incorporated on September 10, 1999, is focused on technologies that treat structural heart disease and critically ill patients. The Firm makes heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Firm conducts activities around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment